Last reviewed · How we verify
Sham ranibizumab
Sham ranibizumab is a placebo used in clinical trials to compare the efficacy of ranibizumab.
Sham ranibizumab is a placebo used in clinical trials to compare the efficacy of ranibizumab. Used for Age-related macular degeneration.
At a glance
| Generic name | Sham ranibizumab |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ranibizumab is an anti-vascular endothelial growth factor (VEGF) antibody fragment, and sham ranibizumab is used as a control to assess the effectiveness of ranibizumab in treating various eye conditions.
Approved indications
- Age-related macular degeneration
Common side effects
- Intraocular inflammation
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (PHASE2)
- A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema (PHASE2)
- Stereotactic Radiotherapy for Wet AMD (STAR) (PHASE3)
- OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (PHASE2)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy (PHASE3)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |